A carregar...
Cost Minimization Analysis of Two Treatment Regimens for Low-Risk Rhabdomyosarcoma in Children: A Report From the Children’s Oncology Group
BACKGROUND: Recent Children’s Oncology Group trials for low-risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 week...
Na minha lista:
| Publicado no: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4370185/ https://ncbi.nlm.nih.gov/pubmed/24453105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24950 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|